Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement
Proportional dose of sublingual fentanyl tablet (NarcoÂ®) based on daily opioid requirement versus intravenous PCA for breakthrough cancer pain: A prospective, randomized, open-label, noninferiority trial.
Cancer Pain|Breakthrough Pain
DRUG: Intravenous Infusion|DRUG: Sublingual Tablet
Change in 11-point scale NRS pain score, Change in pain score compared to baseline Score '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable", 30 minutes after administration
Change in 11-point scale NRS pain score, Change in pain score compared to baseline Score '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable", 15, 45, 60 minutes after administration|sum of pain intensity difference(SPID), sum of pain intensity change compared to baseline difference, 60 minutes after administration|number of additional doses, number of additional doses fentanyl bolus or subligual, immediately after the intervention|Pain interference, Pain interference using BPI-SF, immediately after the intervention|Insomnia, The severity of insomnia using ISI, immediately after the intervention|Depression, The severity of depression using Beck Depression Inventory(BDI) 1-10: These ups and downs are considered normal 11-16: Mild mood disturbance 17-20: Borderline clinical depression 21-30: Moderate depression 31-40: Severe depression over 40: Extreme depression, immediately after the intervention|Satisfaction scale, Satisfaction check using 5 Likert-scale

(1) Very dissatisfied; (2) Not satisfied; (3) Neutral; (4) Satisfied; (5) Very satidfied, immediately after the intervention
Based on the previous around-the-clock analgesic demand compared to IV PCA in cancer pain patients to prepare the basis for the administration of fentanyl sublingual tablets with an initial dose.